Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 24804929.
- Also identified by DOI 10.1007/s00223-014-9858-3.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the first case of teriparatide adjuvant role in the management of a denosumab-induced osteonecrosis of the jaw in a male subject with idiopathic osteoporosis. Clinical benefits and CT healing were obtained within 2 months of teriparatide initiation and denosumab withdrawal. Increase in bone turnover previously described, when denosumab treatment is removed, might have a synergistic effect to the stimulating effect of teriparatide on bone remodeling to promptly heal osteonecrosis of the jaw.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Humanized/adverse effects
- Bone Density Conservation Agents
- Bone Density Conservation Agents/therapeutic use
- Denosumab
- Humans
- Jaw Diseases
- Jaw Diseases/chemically induced
- Jaw Diseases/drug therapy
- Male
- Off-Label Use
- Osteonecrosis
- Osteonecrosis/chemically induced
- Osteonecrosis/drug therapy
- Osteoporosis
- Osteoporosis/drug therapy
- Teriparatide
- Teriparatide/therapeutic use